Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients-Reference-Cited by-同舟云学术

Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients

Published:2020-11-18 Issue:12 Volume:58 Page:
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Luchsinger Larry L.¹^ORCID,Ransegnola Brett P.¹,Jin Daniel K.¹,Muecksch Frauke²,Weisblum Yiska²,Bao Weili³,George Parakkal Jovvian⁴,Rodriguez Marilis⁵,Tricoche Nancy⁴,Schmidt Fabian²,Gao Chengjie⁶,Jawahar Shabnam⁴,Pal Mouli³,Schnall Emily⁴,Zhang Huan⁶,Strauss Donna⁷,Yazdanbakhsh Karina³,Hillyer Christopher D.¹⁷,Bieniasz Paul D.²⁸,Hatziioannou Theodora²

Affiliation:

1. Laboratory of Stem Cell Regenerative Research, Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, USA

2. Laboratory of Retrovirology, The Rockefeller University, New York, New York, USA

3. Laboratory of Complement Biology, Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, USA

4. Laboratory of Molecular Parasitology, Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, USA

5. Laboratory of Blood-Borne Parasites, Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, USA

6. Laboratory of Membrane Biology, Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, USA

7. New York Blood Center Enterprises, New York, New York, USA

8. Howard Hughes Medical Institute, New York, New York, USA

Abstract

The development of neutralizing antibodies (NAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) following infection or vaccination is likely to be critical for the development of sufficient population immunity to drive cessation of the coronavirus disease of 2019 (COVID-19) pandemic. A large number of serologic tests, platforms, and methodologies are being employed to determine seroprevalence in populations to select convalescent plasma samples for therapeutic trials and to guide policies about reopening.

Funder

HHS | NIH | National Institute of Allergy and Infectious Diseases

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.02005-20

Reference35 articles.

1. A new coronavirus associated with human respiratory disease in China

2. A pneumonia outbreak associated with a new coronavirus of probable bat origin

3. The proximal origin of SARS-CoV-2

4. Insight into 2019 novel coronavirus — An updated interim review and lessons from SARS-CoV and MERS-CoV

Cited by 144 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-SARS-CoV-2 Neutralizing Responses in Various Populations: Use of a Rapid Surrogate Lateral Flow Assay and Correlations with Anti-RBD Antibody Levels;Life;2024-06-22

2. Determination of optimum levels of binding antibody units (BAU) of new quantitative chemiluminescent immuno-assay (CLIA) in COVID-19 vaccinated volunteer blood donors;Transfusion and Apheresis Science;2024-06

3. Microfluidic Diffusional Sizing (MDS) Measurements of Secretory Neutralizing Antibody Affinity Against SARS-CoV-2;Annals of Biomedical Engineering;2024-03-08

4. Multicentric evaluation of sensitivity of eight commercial anti-SARS-CoV-2 antibody assays and their correlation to virus neutralization titers in seropositive subjects;Scientific Reports;2024-01-16

5. High diagnostic accuracy of quantitative SARS-CoV-2 spike-binding-IgG assay and correlation with in vitro viral neutralizing activity;Heliyon;2024-01